Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

  • Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government.
  • SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50.
  • Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). 
  • The analysts raised FY22 comirnaty sales estimate to $35 billion from $33 billion, with Pfizer's price target unchanged at $55 and maintaining a Market Perform rating.
  • SVB forecasts Q3 sales of $2 billion, up from the prior outlook of $1.3 billion, and raising Q4 estimate to $2.1 billion from $1.5 billion. 
  • "The contract size (105 million and up to 300 million) and 27% price bump supports Pfizer's plan to raise vaccine prices coming out of the pandemic," SVB notes.
  • At the $30.50 price, another 195 million doses would imply $5.9 billion in additional revenue. These additional doses could also cover each of those individuals for another booster in 2023 and cover the roll-out of the primary series for children under five.
  • Price Action: PFE shares are up 3.31% at $52.64 during the market session on the last check Thursday.
  • Photo by x3 from Pixabay
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.